Headline: BioCryst's ORLADEYO Close to $1B Sales Milestone

[Para 1: The Lead] BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is on track to surpass the $1 billion sales mark for its rare disease therapy ORLADEYO (berotralstat) by the end of 2026, according to preliminary financial data. The drug, approved in 2024 for the treatment of hereditary angioedema, has seen robust uptake, with sales projected to reach $1.05 billion by year-end, up 30% from $800 million in 2025. [Para 2-3: Supporting details & Context] Financial analysts attribute the surge in sales to the drug's efficacy and the growing awareness of hereditary angioedema. ORLADEYO has been pivotal in reducing the frequency of attacks in patients, leading to increased patient retention and new prescriptions. The company's focus on rare diseases and its strong pipeline of innovative therapies continue to attract institutional investors and bolster its market position.